{
    "id": "dbpedia_4324_3",
    "rank": 31,
    "data": {
        "url": "https://www.centerwatch.com/clinical-trials/listings/NCT05399329/study-to-evaluate-real-world-effectiveness-with-palbociclib-plus-endocrine-therapy-as-first-line-second-line-treatment-for-hrher2-advanced-breast-cancer-in-japan",
        "read_more_link": "",
        "language": "en",
        "title": "Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan",
        "top_image": "https://www.centerwatch.com/clinical-trials/listings/NCT05399329/clinical-trials/public/assets/wcg-logo.svg",
        "meta_img": "https://www.centerwatch.com/clinical-trials/listings/NCT05399329/clinical-trials/public/assets/wcg-logo.svg",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "breast cancer | cancer treatments",
            "enroll clinical trial",
            "find clinical trials",
            "search clinical trial",
            "clinical study",
            "clinical research",
            "medical testing",
            "clinical study",
            "clinical trial recruitment",
            "patient recruitment"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting. For the purposes of this study, analyses will be descriptive in nature. No formal hypothesis testing is planned.",
        "meta_lang": "en",
        "meta_favicon": "clinical-trials/public/assets/wcg-logo.svg",
        "meta_site_name": "",
        "canonical_link": "https://www.centerwatch.com/clinical-trials/listings/NCT05399329/study-to-evaluate-real-world-effectiveness-with-palbociclib-plus-endocrine-therapy-as-first-line-second-line-treatment-for-hrher2-advanced-breast-cancer-in-japan/study-to-evaluate-real-world-effectiveness-with-palbociclib-plus-endocrine-therapy-as-first-line-second-line-treatment-for-hrher2-advanced-breast-cancer-in-japan",
        "text": "This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting. For the purposes of this study, analyses will be descriptive in nature. No formal hypothesis testing is planned."
    }
}